• 10 May 2013

    Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology that creates ‘topical-by-design’ drugs.

  • 24 April 2013

    Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, for inflammation and pain, today announces that it has been awarded a prestigious European Union Framework Programme 7 (FP7) grant in the ‘Health: Systems Medicine’ work programme theme. The €1.98m FP7 grant will be used to develop the next generation of Creabilis’ ‘topical-by-design’ pre-clinical candidates to complement its existing clinical portfolio. The candidates will be developed using Creabilis’ proprietary Low Systemic Exposure (LSE) technology.

  • 26 March 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimumcontact force (CF), as well as minimum Force Time Integral (FTI™), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF). Published in the April 2013 issue of the American Heart Association journal Circulation: Arrhythmia and Electrophysiology, the newly created guidelines call for a CF target of 20 g (and minimum CF of 10 g) and minimum FTI of 400 gs per individual ablation lesion.

  • 22 March 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today its decision to withdraw, for strategic reasons, the Marketing Authorization Application (MAA) for Raxone® as a potential therapy for Leber's Hereditary Optic Neuropathy (LHON). Santhera now plans to file a new application based on emerging clinical evidence supporting the efficacy of Raxone® in the treatment of LHON. This strategy is expected to increase the probability of a successful MAA outcome and is contingent on the availability of sufficient financial resources or on the outcome of ongoing licensing and M&A discussions.

  • 13 March 2013

    Sequana Medical is pleased to announce that Prof. Giorgio Enrico Gerunda from the University of Modena and Reggio Emilia has implanted Italy’s first two patients with the alfapump system. The alfapump system is a fully implantable battery-powered pump that is designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from advanced liver disease.